Ibsrela (Tenapanor HCl) Patent Expiration, LOE Window & CMS Spending
Ibsrela (Tenapanor HCl) by Ardelyx: FDA Orange Book core substance LOE 2033-08-01 (last listed 2042-11-26), 0 AB generics, $101.4M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ardelyx |
| FDA Application & Pathway | N211801 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2033-08-01 |
| Last Listed Patent or Exclusivity Date | 2042-11-26 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $101.4M |
| 2024 Medicare Part D Spend | $68.4M |
| 2024 Medicaid Spend | $33.0M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 20.2% 2-yr change) |